Company intelligence / Profile preview
Bioplus
- Ownership
- Private
- Development stage
- Commercial
Overview
Bioplus Life Sciences has over 75 years of experience serving the pharmaceutical industry with high-quality products and services. The company has evolved into a late-stage clinical biotech with two Phase 3-ready programs addressing large unmet needs—most notably, an oral therapy for pediatric myopia ("7-MX"). It also recently secured EFSA approval for its algal DHA oil/powder in infant formula. The company maintains robust R&D investment and global manufacturing capacity across multiple dosage forms.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculePeptides & ProteinsFermentation-derived products
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Bioplus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bioplus.